Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CBL
REST API REST API
Homo sapiens
CBL is differentially expressed in 270 experiments: 123 organism parts: bone marrow, skeletal muscle, ... (121 more);, 153 disease states: normal, breast carcinoma, ... (151 more);, 80 cell types 376 cell lines 37 compound treatments and 79 other conditions.
Synonyms CBL2, RNF55, c-Cbl
Orthologs D4A407_RAT (Rattus norvegicus)   ENSCING00000002655 (Ciona intestinalis)   cbl (Danio rerio)   Cbl (Mus musculus)   CBL (Bos taurus)   Cbl (Drosophila melanogaster)   cbl (Xenopus laevis)   CBL (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, ligase activity, plasma membrane, negative regulation of epidermal growth factor receptor signaling pathway, protein binding, regulation of transcription, DNA-dependent, cytoplasm, epidermal growth factor receptor signaling pathway, transcription, DNA-dependent, protein ubiquitination, flotillin complex, negative regulation of apoptosis, SH3 domain binding, ephrin receptor binding, signal transducer activity, cell surface receptor linked signaling pathway, nucleus, ubiquitin-protein ligase activity, calcium ion binding, zinc ion binding, phosphotyrosine binding, positive regulation of receptor-mediated endocytosis, sequence-specific DNA binding transcription factor activity, positive regulation of phosphatidylinositol 3-kinase cascade, regulation of signaling
InterPro Term UBA/transl_elong_EF1B_N_euk, UBA/transl_elong_EF1B_N, Znf_RING, Znf_C3HC4_RING-type, Adaptor_Cbl_SH2-like, Adaptor_Cbl_EF_hand-like, Adaptor_Cbl_N_hlx
UniProt Accession P22681
Gene-Disease Assocation NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC
Search EB-eye ENSG00000110395
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-MTAB-62, E-GEOD-4219, ... (32 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
A549
2
E-GEOD-3202, E-GEOD-6013
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
DU145
2
E-GEOD-17482, E-GEOD-20089
HL-60
2
E-MTAB-37, E-GEOD-24147
KG1
2
E-MTAB-37, E-GEOD-24147
370 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-GEOD-4219, E-GEOD-13909, E-GEOD-20677, ... (40 experiments)

Factor Value U/D Experiments
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
1
2
E-TABM-130, E-TABM-145
fibroblast
2
E-GEOD-26672, E-GEOD-3920
macrophage
2
E-GEOD-22373, E-GEOD-8286
basophil
1
E-GEOD-3982
activated B-cell
1
E-MEXP-2360
74 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1615, E-GEOD-15960, E-MEXP-1121, E-MEXP-2280, ... (52 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-7307
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-7307
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
control
1
2
E-GEOD-8121, E-GEOD-16728, E-GEOD-16363
147 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (25 experiments)

Factor Value U/D Experiments
phenol
1
E-GEOD-6907
AMP
1
1
E-MEXP-2285
BCR/ABL1
1
1
E-GEOD-15811
filtered air
1
E-TABM-127
4,5-dianilinophthalimide
1
1
E-GEOD-5258
TGF
1
E-GEOD-15205
31 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
32 years
1
1
E-GEOD-4922
32
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-19246, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-7011, E-MEXP-2657, E-GEOD-12773, E-TABM-127, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (37 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-GEOD-12108, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22229, E-GEOD-21750, E-GEOD-1657, E-GEOD-4600

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-101, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-4922

Processing time: 0.271 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM